Company: PMVP
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001140361-25-015610
Chunk: 32

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 32
---
 |   503,300 |     |           | 172,000 |     |                 | — |     |               | — |     |              | 1,097,198 |     |           |

| (1) | The amounts reported represent the aggregate grant date fair value of options calculated in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718-Compensation-Stock Compensation (“ASC 718”). Such grant-date fair value does not take into account any estimated forfeitures related to performance or service vesting conditions. Information about the assumptions used in the calculation of these amounts are included in Note 2 and Note 8 to the Company’s financial statements for the year ended December 31, 2024 included in the Company’s Annual Report on Form 10-K for such year. The amounts reported represent grants of options pursuant to our 2020 Equity Incentive Plan as described further in the table of outstanding equity awards below. Additionally, solely for fiscal year 2024, the amounts disclosed include the incremental fair value, calculated in accordance with ASC 718, associated with new option grants that were exchanged for prior option grants pursuant to the Tender Offer Statement on Schedule TO filed with the Securities and Exchange Commission on July 16, 2024, as amended. |

| (2) | The 2024 amounts reported cash bonuses earned under our 2024 bonus plan based upon the achievement of various development, pipeline, and corporate goals for the year ended December 31, 2024, which were paid in 2025. |

| (3) | Mr. Carulli became our Chief Financial Officer in January 2024 and was not a named executive officer in 2023. |

19

TABLE OF CONTENTS

2024 Bonus Plan Each named executive officer has an established target bonus amount as set forth in the section below titled “—Employment Arrangements with our Named Executive Officers.” In 2024, our named executive officers were eligible for non-equity incentive compensation pursuant to the terms of a bonus plan for 2024, with the actual amount payable tied to the achievement of various development, pipeline, and corporate goals. The amount earned by our named executive officers is set forth in our Summary Compensation Table above. Employment Arrangements with our Named Executive Officers David H. Mack, Ph.D. We entered into a confirmatory employment letter with Dr. Mack, our President and Chief Executive Officer, on August 17, 2020. The employment letter has no specific term and